Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML Transcript

Core Insights - Kura Oncology hosted an ASH 2025 analyst and investor event, highlighting significant advancements in menin inhibitors for acute leukemia [1][2] Company Overview - The presentation was led by Troy Wilson, the President and CEO of Kura Oncology, indicating a focus on recent developments and data presented at the conference [1] - The agenda included a review of data presented in an oral session at ASH, emphasizing the importance of the findings for the company and the industry [2]